Back to Search
ROBERT SALAZAR, MD
MD
Pulmonary Disease Physician
NPI: 1508800251IndividualAccepts Medicare
Specialties, Licenses & Credentials
Pulmonary Disease PhysicianPrimary
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
K2276(TX)
Education
OTHER
Class of 1989
Research & Publications (20)
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
PMID 19370414·Breast Cancer Res Treat·2010
8-other
PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts.
PMID 19586538·Mol Cancer·2009
8-other
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.
PMID 19423537·Cancer Epidemiol Biomarkers Prev·2009
4-observational
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
PMID 18451254·Clin Cancer Res·2008
4-observational
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.
PMID 18437204·PLoS Genet·2008
8-other
Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
PMID 18281545·Clin Cancer Res·2008
3-trial
Differences in patient postoperative and long-term outcomes between obstructive and perforated colonic cancer.
PMID 18361923·Am J Surg·2008
4-observational
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
PMID 18335219·Cancer Chemother Pharmacol·2008
3-trial
PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.
PMID 19002188·Br J Cancer·2008
7-preclinical
Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia.
PMID 18186055·Am J Med Genet B Neuropsychiatr Genet·2008
8-other
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
PMID 18172273·Clin Cancer Res·2008
3-trial
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma.
PMID 17934252·Neuroendocrinology·2008
8-other
Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis.
PMID 18334708·J Natl Cancer Inst·2008
1-meta
Tonatiuh II: assisting manipulator for laparoscopic surgery.
PMID 17917995·Minim Invasive Ther Allied Technol·2007
7-preclinical
[Long-term results of emergency surgery for colon cancer compared with elective surgery].
PMID 17785142·Cir Esp·2007
4-observational
Update in the management of ovarian and cervical carcinoma.
PMID 17652058·Clin Transl Oncol·2007
8-other
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.
PMID 17639039·Endocr Relat Cancer·2007
6-review
Oxidation of C4-hydroxyphenyl 1,4-dihydropyridines in dimethylsulfoxide and its reactivity towards alkylperoxyl radicals in aqueous medium.
PMID 17446078·Bioorg Med Chem·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 19255 PARK ROW STE 102
HOUSTON, TX 77084 - Phone
- (281) 492-0363
Quick Facts
- NPI
- 1508800251
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile